Join Growin Stock Community!

Drugs made in america acquisition corp. rightsDMAAR.US Overview

US StockIndustrials
(No presentation for DMAAR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DMAAR AI Insights

DMAAR Overall Performance

DMAAR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DMAAR Recent Performance

-

Drugs made in america acquisition corp. rights

-1.72%

Avg of Sector

-2.16%

S&P500

DMAAR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DMAAR Key Information

DMAAR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DMAAR Profile

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Price of DMAAR

DMAAR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DMAAR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DMAAR's latest earnings report released?

    The most recent financial report for Drugs made in america acquisition corp. rights (DMAAR) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DMAAR's short-term business performance and financial health. For the latest updates on DMAAR's earnings releases, visit this page regularly.

  • How much cash does DMAAR have?

    At the end of the period, Drugs made in america acquisition corp. rights (DMAAR) held Total Cash and Cash Equivalents of 822, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.